India-discovered levonadifloxacin & alalevonadifloxacin: A review on susceptibility testing methods, CLSI quality control and breakpoints along with a brief account of their emerging therapeutic profile as a novel standard-of-care.
Veeraraghavan B, Bakthavatchalam YD, Manesh A, Lal B, Swaminathan S, Ansari A, Subbareddy K, Rangappa P, Choudhuri AH, Nagvekar V, Mehta Y, Appalaraju B, Baveja S, Baliga S, Shenoy S, Bhardwaj R, Kongre V, Dattatraya GS, Verma B, Mukherjee DN, Gupta S, Shanmugam P, Iravane J, Mishra SR, Barman P, Chopra S, Hariharan M, Surpam R, Pratap R, Turbadkar D, Taklikar S; Drug Discovery group, Wockhardt.
Veeraraghavan B, et al. Among authors: pratap r.
Indian J Med Microbiol. 2023 Jan-Feb;41:71-80. doi: 10.1016/j.ijmmb.2022.11.005. Epub 2022 Dec 9.
Indian J Med Microbiol. 2023.
PMID: 36509611
Review.